Morgan Stanley upgraded Merck to Overweight with a $179 price target, citing a 17.6% upside following successful Phase 3 results of Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda. The vaccine showed significant improvement in delaying cancer recurrence and metastasis in high-risk skin cancer patients, marking a major breakthrough in cancer treatment. Merck's shares rose 12.61% to $152.22, reflecting strong investor confidence in this innovative therapy. This development positions Merck for potential growth ahead as the first positive Phase 3 result for an mRNA cancer therapy.
The Schwab U.S. Dividend Equity ETF (SCHD) has outperformed the S&P 500 in 2026, returning 27.92% through August compared to the S&P 500's 13.85%. This strong performance is due to SCHD's focus on dividend-paying sectors like semiconductors, healthca...
In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products b...
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Moderna's stock surged over 125% in one week, driven by positive interim results from its Phase 3 trial of a personalized mRNA cancer vaccine for high-risk melanoma patients. The trial, conducted with partner Merck, showed success without new safety ...
Merck & Co. surged to all-time highs following positive Phase 3 trial results of its melanoma vaccine developed with Moderna. The company maintains a Buy rating due to strong growth in oncology, solid free cash flow, and potential for further stock g...
